Vir Biotechnology, Inc. Operating Income
Vir Biotechnology, Inc. (VIR) reported Operating Income of $73.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Vir Biotechnology, Inc. operating income (loss) for the quarter ending 2026-06-30 was $73.47M.
- Vir Biotechnology, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$132.29M.
- Vir Biotechnology, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$47.92M.
- Vir Biotechnology, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$173.44M.
- Vir Biotechnology, Inc. operating income (loss) for fiscal 2025 was -$479.33M.
- Vir Biotechnology, Inc. operating income (loss) for fiscal 2024 was -$587.16M.
- Vir Biotechnology, Inc. operating income (loss) for fiscal 2023 was -$684.30M, a 182.14% decline from fiscal 2022.
- Vir Biotechnology, Inc. operating income (loss) for fiscal 2022 was $833.07M, a 98.00% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $73.47M 10-Q · filed 2026-08-05 | -$58.82M 10-Q · filed 2026-08-05 | -$106.74M derived: sum of 3 quarters · filed 2026-08-05 | -$280.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$132.29M 10-Q · filed 2026-05-07 | -$180.21M derived: sum of 2 quarters · filed 2026-05-07 | -$353.65M derived: sum of 3 quarters · filed 2026-05-07 | -$472.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$47.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$221.36M derived: sum of 2 quarters · filed 2026-02-23 | -$339.78M derived: sum of 3 quarters · filed 2026-08-05 | -$479.33M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$173.44M 10-Q · filed 2025-11-05 | -$291.86M derived: sum of 2 quarters · filed 2026-08-05 | -$431.41M 10-Q · filed 2025-11-05 | -$548.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$118.42M 10-Q · filed 2026-08-05 | -$257.96M 10-Q · filed 2026-08-05 | -$375.11M derived: sum of 3 quarters · filed 2026-08-05 | -$606.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$139.55M 10-Q · filed 2026-05-07 | -$256.70M derived: sum of 2 quarters · filed 2026-05-07 | -$488.00M derived: sum of 3 quarters · filed 2026-05-07 | -$646.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$117.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$348.45M derived: sum of 2 quarters · filed 2026-02-23 | -$507.08M derived: sum of 3 quarters · filed 2026-02-23 | -$587.16M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$231.30M 10-Q · filed 2025-11-05 | -$389.93M derived: sum of 2 quarters · filed 2025-11-05 | -$470.01M 10-Q · filed 2025-11-05 | -$609.03M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$158.63M 10-Q · filed 2025-08-06 | -$238.71M 10-Q · filed 2025-08-06 | -$377.73M derived: sum of 3 quarters · filed 2026-02-23 | -$564.46M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$80.08M 10-Q · filed 2025-05-08 | -$219.10M derived: sum of 2 quarters · filed 2026-02-23 | -$405.83M derived: sum of 3 quarters · filed 2026-02-23 | -$621.01M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$139.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$325.75M derived: sum of 2 quarters · filed 2026-02-23 | -$540.93M derived: sum of 3 quarters · filed 2026-02-23 | -$684.30M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$186.73M 10-Q · filed 2024-11-04 | -$401.92M derived: sum of 2 quarters · filed 2024-11-04 | -$545.29M 10-Q · filed 2024-11-04 | -$695.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$215.19M 10-Q · filed 2024-08-01 | -$358.56M 10-Q · filed 2024-08-01 | -$509.06M derived: sum of 3 quarters · filed 2025-02-27 | -$314.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$143.37M 10-Q · filed 2024-05-03 | -$293.87M derived: sum of 2 quarters · filed 2025-02-27 | -$98.91M derived: sum of 3 quarters · filed 2025-02-27 | -$324.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$150.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $44.46M derived: sum of 2 quarters · filed 2025-02-27 | -$180.76M derived: sum of 3 quarters · filed 2025-02-27 | $833.07M 10-K · filed 2025-02-27 |
| 2022-09-30 | $194.96M 10-Q · filed 2023-11-03 | -$30.26M derived: sum of 2 quarters · filed 2023-11-03 | $983.57M 10-Q · filed 2023-11-03 | $1.56B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$225.22M 10-Q · filed 2023-08-04 | $788.61M 10-Q · filed 2023-08-04 | $1.36B derived: sum of 3 quarters · filed 2024-02-26 | $1.31B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.01B 10-Q · filed 2023-05-08 | $1.59B derived: sum of 2 quarters · filed 2024-02-26 | $1.53B derived: sum of 3 quarters · filed 2024-02-26 | $1.59B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $571.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $518.37M derived: sum of 2 quarters · filed 2024-02-26 | $579.38M derived: sum of 3 quarters · filed 2024-02-26 | $420.75M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$53.38M 10-Q · filed 2022-11-03 | $7.63M derived: sum of 2 quarters · filed 2022-11-03 | -$151.00M 10-Q · filed 2022-11-03 | -$259.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $61.02M 10-Q · filed 2022-08-09 | -$97.62M 10-Q · filed 2022-08-09 | -$206.02M derived: sum of 3 quarters · filed 2023-02-28 | -$293.63M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$158.63M 10-Q · filed 2022-05-05 | -$267.04M derived: sum of 2 quarters · filed 2023-02-28 | -$354.65M derived: sum of 3 quarters · filed 2023-02-28 | -$383.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$108.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$196.02M derived: sum of 2 quarters · filed 2023-02-28 | -$225.07M derived: sum of 3 quarters · filed 2023-02-28 | -$296.98M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$87.61M 10-Q · filed 2021-11-04 | -$116.67M derived: sum of 2 quarters · filed 2021-11-04 | -$188.58M 10-Q · filed 2021-11-04 | -$252.34M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$29.05M 10-Q · filed 2021-08-05 | -$100.96M 10-Q · filed 2021-08-05 | -$164.72M derived: sum of 3 quarters · filed 2022-02-28 | -$212.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$71.91M 10-Q · filed 2021-05-06 | -$135.67M derived: sum of 2 quarters · filed 2022-02-28 | -$183.35M derived: sum of 3 quarters · filed 2022-02-28 | -$219.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$63.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$111.44M derived: sum of 2 quarters · filed 2022-02-28 | -$147.21M derived: sum of 3 quarters · filed 2022-02-28 | -$177.98M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$47.68M 10-Q · filed 2020-11-10 | -$83.45M derived: sum of 2 quarters · filed 2020-11-10 | -$114.22M 10-Q · filed 2020-11-10 | -$141.01M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$35.77M 10-Q · filed 2020-08-11 | -$66.54M 10-Q · filed 2020-08-11 | -$93.33M derived: sum of 3 quarters · filed 2021-02-25 | -$127.68M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$30.77M 10-Q · filed 2020-05-12 | -$57.57M derived: sum of 2 quarters · filed 2021-02-25 | -$91.91M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$61.14M derived: sum of 2 quarters · filed 2021-02-25 | -$118.69M 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$34.35M 10-Q · filed 2019-11-19 | -$91.90M 10-Q · filed 2019-11-19 | ||
| 2017-12-31 | -$81.50M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |